Market capitalization | €402.30m |
Enterprise Value | €401.95m |
P/E (TTM) P/E ratio | 51.06 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.86 |
P/S ratio (TTM) P/S ratio | 0.86 |
P/B ratio (TTM) P/B ratio | 4.46 |
Dividend yield | 1.23% |
Last dividend (FY23) | €0.17 |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
3 Analysts have issued a Ion Beam Applications forecast:
3 Analysts have issued a Ion Beam Applications forecast:
Jun '24 |
+/-
%
|
||
Revenue | 466 466 |
26%
26%
|
|
Gross Profit | 159 159 |
46%
46%
|
|
EBITDA | 39 39 |
1,521%
1,521%
|
EBIT (Operating Income) EBIT | 27 27 |
294%
294%
|
Net Profit | 7.85 7.85 |
140%
140%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ion Beam Applications SA engages in the design, manufacture, and marketing of cancer treatment and diagnosis equipment. It operates through the Proton Therapy and Other Accelerators; and Dosimetry segments. The Proton Therapy and Other Accelerators segment include development, fabrication, and services associated with medical and industrial particle accelerators and proton therapy systems. The Dosimetry segment comprises activities that offer a full range of solutions and services that maximize efficiency and minimize errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company was founded by Yves Jongen on March 28, 1986 and is headquartered in Louvain-la-Neuve, Belgium.
Head office | Belgium |
CEO | Olivier Legrain |
Employees | 1,986 |
Founded | 1986 |
Website | www.iba-worldwide.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.